Doctors from Dartmouth-Hitchcock Hospital in February reported that there was more than a 2 times greater risk of bleeding in the brain-intracranial hemorrhaging-in users of the NOAC category of drugs than with the old standby warfarin (Coumadin). This was in patients who had stenting of heart vessels and who were taking Plavix as an antiplatelet drug but also needed an anticoagulant.
“NOAC” is a term the medical profession has begun to use for the “new oral anticoagulants.” The first two in this group are Xarelto and Pradaxa, and both of these were involved in the study just presented, at the International Stroke Conference in Los Angeles. Eliquis is a newer NOAC, and it seems reasonable to assume its use too would increase the risk of brain bleeds.
Dr. Kimon Bekelis and others at the New Hampshire hospital system studied a large number of patients who needed anticoagulants after they had the stenting procedure and were taking Plavix as an antiplatelet drug.
Our firm has started a number of suits involving the death due to stroke of patients who were on Xarelto or Eliquis. They had developed sudden bleeding in the brain, which could not be controlled, since there was no reversal agent, as there is for someone who bleeds while on warfarin. We welcome all calls about similar events in other users. You can contact us online or at 800-349-0004 to speak with a knowledgeable drug liability attorney.